BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34055619)

  • 1. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
    Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
    Front Oncol; 2021; 11():650153. PubMed ID: 34055619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
    Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
    Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.
    Ma C; Bao Y; Xu J; Xiao B; Li H
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):47-62. PubMed ID: 36528831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 7. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
    Liu J; Deng W; Xiao Z; Huang X; Lin M; Long Z
    J Immunol Res; 2022; 2022():8976179. PubMed ID: 36157883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma.
    Ye F; Wu P; Zhu Y; Huang G; Tao Y; Liao Z; Guan Y
    Front Genet; 2022; 13():989081. PubMed ID: 36338975
    [No Abstract]   [Full Text] [Related]  

  • 10. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
    Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
    Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer.
    Wang L; Bi J; Li X; Wei M; He M; Zhao L
    J Cancer; 2020; 11(22):6530-6544. PubMed ID: 33046974
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
    Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
    Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a cellular senescence-related-lncRNA (SRlncRNA) signature to predict the overall survival of glioma patients and the tumor immune microenvironment.
    Liu Q; Bao H; Zhang S; Song T; Li C; Sun G; Sun X; Fu T; Wang Y; Liang P
    Front Genet; 2023; 14():1096792. PubMed ID: 36911393
    [No Abstract]   [Full Text] [Related]  

  • 16. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
    Liu J; Lu J; Li W
    Front Immunol; 2021; 12():738068. PubMed ID: 34630418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
    Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
    Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
    Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
    Front Oncol; 2021; 11():778637. PubMed ID: 35004299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
    He Y; Ye Y; Tian W; Qiu H
    Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
    [No Abstract]   [Full Text] [Related]  

  • 20. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
    Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.